Among the seven patients in our study without metaphases available, we found that three had FLT3/ITD+ (42.8%), thus showing the need to apply several methods in order to comprehensively identify the disease, using other resources such as the PCR technique to characterize AML patients.26 This evidence concerns the gene FLT3 and acute myeloid leukemia.